Date: 2013-06-24
Type of information:
phase: 3
Announcement: presentation of five long-term Phase III studies (Harmony 1 to 5) at the American Diabetes Association Meeting (ADA) in Chicago.
Company: GSK (UK)
Product: albiglutide
Action mechanism: Albiglutide is an injectable form of human GLP-1 - a peptide that acts throughout the body to help maintain normal blood-sugar levels and to control appetite. It fuses human GLP-1 to human albumin. It is designed to have the potential to extended duration of action and allow for weekly or less-frequent injections.
Disease: type 2 diabetes
Therapeutic area: Metabolic diseases
Country:
Trial details: The Harmony Phase III programmeThe Phase III clinical development programme for albiglutide comprised eight individual studies (Harmony 1 to Harmony 8) involving over 5,000 patients. The programme investigated the efficacy, tolerability and safety, including cardiovascular safety, of albiglutide as mono- and add-on therapy, in patients with type 2 diabetes. All eight studies have completed.
Latest
news: * On June 24, 2013, GSK has presentend data from five long-term Phase III studies (Harmony 1 to 5) comparing albiglutide to placebo and a range of active comparators at the American Diabetes Association Meeting (ADA) in Chicago. The active comparators in the studies were insulin, a sulphonylurea (SU), a thiazolidinedione (TZD), and a dipeptidyl peptidase four inhibitor (DPP-4). The primary efficacy endpoint for these studies was the change from baseline in HbA1c compared to placebo and/or active comparators assessed after one or two years of treatment. Secondary endpoints included fasting plasma glucose (FPG) and weight. These studies were specifically designed to assess durability of albiglutide effect on HbA1c and other continuous variables when used in various combination therapies, at different stages of the disease, and in various degrees of renal impairment. Albiglutide achieved the primary efficacy endpoint in these five studies, although a hierarchical analysis of noninferiority to pioglitazone was not met in one study, as noted below. The most commonly reported adverse reactions in these studies were gastrointestinal (GI) complaints, primarily nausea and diarrhoea, and injection site reactions.
In Harmony 1 (Abstract number: 2013-LB-5644), a 3-year, 52-week primary endpoint, randomised, double-blind, placebo-controlled study, patients inadequately controlled on a current regimen of pioglitazone with or without metformin were administered either 30mg albiglutide or placebo. At the 52 week primary endpoint, albiglutide combination therapy demonstrated a statistically significant reduction in HbA1c from baseline compared to placebo (treatment difference of -0.8% (p<0.0001)). Forty-four percent of the albiglutide patients achieved an HbA1c target of less than 7% compared to 15% of those on placebo. There was a non-significant difference in weight with albiglutide versus placebo (treatment difference: -0.2kg). Adverse events of nausea and vomiting were comparable between albiglutide and placebo, while diarrhoea (11.3% vs. 8.6%) and injection site reactions (11.3% vs. 7.9%) were higher for albiglutide vs placebo. The rate of severe hypoglycaemia in the albiglutide arm of the study was 1%.
Harmony 2 (Abstract number: 2013-LB-5749), a 3-year, 52-week primary endpoint randomised, double-blind, placebo-controlled study compared albiglutide 30mg or 50mg vs placebo in patients on diet and exercise in drug naïve patients. At 52 weeks, both albiglutide doses demonstrated statistically significant HbA1c reductions over placebo (-0.84% 30mg albi; -1.0% 50mg albi; p<0.0001). Weight (kg) decreased in all groups (-0.9/-0.4/-0.7kg placebo/30mg albi/50mg albi). GI adverse event rates for nausea (8%/10%/9%), diarrhoea (12%/10%/13%) and vomiting (1%/3%/3%) were similar across placebo/albi30mg/albi50mg, while injection site reactions (10%/18%/22%) were higher in the two albiglutide arms. There were no reports of severe hypoglycaemia in the albiglutide arm of the study.
Harmony 3 (Abstract number: 2013-LB-5750) was a 3-year, 104-week primary endpoint, randomised, double-blind, placebo- and active-controlled, parallel-group study comparing the efficacy and safety of albiglutide, sitagliptin, glimepiride, and placebo in subjects taking and inadequately controlled on metformin. At Week 104, the reduction in HbA1c was statistically significant in the albiglutide group compared to those treated with placebo (-0.9%; p<0.0001), sitagliptin (-0.4%; p=0.0001), or glimepiride (-0.3%; p=0.003). Weight loss in the albiglutide group was statistically significant compared to the glimepiride group (-2.4kg; p<0.0001) and similar to the sitagliptin (-0.4kg) and placebo (-0.2kg) groups. GI adverse events during 2 years of observation included nausea (11%/7%/6%/10%), vomiting (1%/4%/4%/6%) and diarrhoea (11%/9%/9%/13%) across the placebo/sitagliptin/glimepiride/albi arms; injection site reactions were (5%/6%/8%/17%), respectively. There were no reports of severe hypoglycaemia in the albiglutide arm of the study.
In Harmony 4 (Abstract number: 2013-LB-5751), a 3-year, 52-week primary endpoint, randomised, open-label study, albiglutide was compared to insulin glargine, in subjects on metformin with or without an SU. Both groups achieved a similar reduction in HbA1c (-0.7% and -0.8% in the albiglutide and insulin glargine groups). Treatment difference 0.11% with 95% CI (0.04%, 0.27%) indicates non-inferiority of albiglutide versus insulin glargine. Patients on albiglutide lost weight (-1.1kg) while those on insulin glargine experienced weight gain (+1.6kg) with a treatment difference of 2.6kg (p<0.001). GI adverse events though week 52 for albiglutide/glargine arms included nausea (9.9%/3.7%), vomiting (3.8%/3.7%) and diarrhoea (7.5%/4.1%). Injection site reactions were higher for albiglutide vs. glargine (13.9% vs. 8.7%, respectively). The rate of severe hypoglycaemia in the albiglutide arm of the study was 0.4%.
The Harmony 5 study (Abstract: 2013-LB-5752) was a 3-year, 52-week primary endpoint, randomised, double-blind study to evaluate the efficacy and safety of albiglutide compared to placebo and pioglitazone (pio) in patients currently on a background therapy of metformin and glimerpiride. Stepwise statistical analysis was first versus placebo, followed by noninferiority (margin 0.30%) testing vs pio. At Week 52, the reduction in HbA1c in the albiglutide group was statistically significant versus the placebo group (-0.9%; p<0.001). Non-inferiority was not achieved versus the pio group (0.3%; p=0.27). GI adverse events at Week 52 for nausea (3.5%/4.3%/9.6%), diarrhoea (2.6%/5.4%/8.9%) and vomiting (0.9%/1.8%/2.6%) across the placebo/pio/albiglutide arms were higher for albiglutide, as were injection site reactions (3.5%/3.2%/12.9%). The rate of severe hypoglycaemia in the albiglutide arm of the study was 0.4%.
Data from one other Phase III study was also presented at the ADA meeting, Harmony 8 (68-OR), a 52-week controlled trial in which albiglutide was compared to a DPP-4 inhibitor, sitagliptin, in patients with renal impairment (results previously announced).
Albiglutide is currently undergoing regulatory review for the treatment of type two diabetes in the US and European Union.
